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Abstract
Approximately 7% of women with breast cancer are diagnosed before the age of 40 years, and this
disease accounts for more than 40% of all cancer in women in this age group. Survival rates are worse
when compared to those in older women, and multivariate analysis has shown younger age to be an
independent predictor of adverse outcome. Inherited syndromes, specifically BRCA1 and BRCA2,
must be considered when developing treatment algorithms for younger women. Chemotherapy,
endocrine, and local therapies have the potential to significantly impact both the physiologic health
—including future fertility, premature menopause, and bone health—and the psychological health
of young women as they face a diagnosis of breast cancer.
Although a diagnosis of breast cancer is distressing at any age, this occurrence in young women
is fraught with several unique challenges. This article reviews the distinct epidemiology,
etiology, clinicopathologic characteristics, biology, treatment strategies, outcomes, and
psychosocial challenges of breast cancer before 40 years of age. Also included in this review
are issues of familial breast cancer, fertility, premature menopause, breast cancer during
pregnancy, and bone health. The US Surveillance, Epidemiology and End Results (SEER)
database was the source of data for the tables and graphs presented here.1
Epidemiology
The American Cancer Society (ACS) estimates that 182,460 women in the United States were
diagnosed with breast cancer in 2008 and that 40,480 women died of the disease during the
year.2 The incidence of breast cancer appears to have a sigmoid function in women less than
55 years of age (Figure 1, lower panel), with 6.6% of all cases diagnosed before age 40, 2.4%
diagnosed before age 35, and 1% diagnosed before age 30 (Figure 2, inset). The individual
average risk of a woman developing breast cancer was 1 in 173 by the age of 40 and
approximately 1 in 1,500 by the age of 30 (Table 1). Of all cancers diagnosed among women,
more than 40% is breast cancer by the age of 40, 20% by the age of 30, and slightly more than
2% by 20 years of age (Figure 1, upper panel).
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The overall incidence of breast cancer in males is approximately 1/100th that of the rate in
females. The age-dependence differs also, in that breast cancer occurs at older ages in males,
with only 2.6% of all cases in men occurring before age 40 years. Hence, breast cancer in males
is not reviewed further in this article.
Although the incidence of breast cancer in females younger than 40 years of age has remained
stable for the past 30 years (Figures 3 and 4), the incidence in older women had increased
steadily (Figure 3) until it peaked in 2000 then declined steadily thereafter (Figure 4). This
decrease has been attributed to the reduction in the use of hormone replacement therapy.3
The incidence of breast cancer in young women in the United States also varies according to
race and ethnicity. In women over 45, breast cancer is more common in whites than blacks.
However, black women under age 35 have more than twice the incidence of invasive breast
cancer and three times the breast cancer mortality of young white women.4-6 In contrast, native
American women aged 20-44 have a lower incidence of breast cancer (relative risk [RR] = 0.7)
compared to the general population.7 Women of all ages with low socioeconomic status, as
well as young black and Hispanic women, and native American women have an increased
likelihood of presenting with advanced disease.8-10
Personal risk factors for the early onset of breast cancer differ in interesting ways from those
for postmenopausal breast cancer. A positive family history of cancer is a very strong risk
factor for women under 35 years of age (RR = 3.22)4 and suggests the presence of a familial
cancer syndrome.
Breast cancer at an early age is more likely to be associated with an increased familial risk,
especially in women harboring a germline BRCA1 mutation.11 In a study of women with breast
cancer diagnosed before age 30, BRCA1, BRCA2, and TP53 mutations were found in about
half who had strong family histories of breast cancer and in less than 10% of women with non-
familial breast cancer.12 Patients with familial PTEN mutations (Cowden syndrome) also have
an increased risk for early breast cancer.13
There is evidence that breast cancer risk is positively associated with body mass index in
postmenopausal women. A large population-based study evaluating approximately 50,000
women indicated that the combination of obesity, high energy (caloric) intake, and sedentary
lifestyle is a risk factor in premenopausal women.14
Hormonal risk factors are somewhat different for women aged less than 35 years in comparison
to older women. Recent oral contraceptive use is a risk factor for early-onset breast cancer (RR
= 2.26), particularly for estrogen receptor (ER)-negative tumors. For women aged less than 35
years, early childbearing and multiparity are risk factors, due to a short-term elevation in breast
cancer risk for several months immediately following a birth.15
Other risk factors for breast cancer in premenopausal women include a history of prior mantle
irradiation for Hodgkin lymphoma, early age at menarche, heavy alcohol consumption, and a
high intake of red meat.4,13,16 Intense physical activity and a high intake of certain fruits and
vegetables (eg, tomatoes) have been associated with a decreased breast cancer risk in
premenopausal women.17,18
Increased mammographic density is a risk factor for breast cancer at all ages.19 In
premenopausal women, one study suggests that regular ingestion of multivitamin-multimineral
supplements may be associated with higher mean breast density.20 A recent study examined
the effect of raloxifene therapy on mammographic breast density in premenopausal women at
high risk for breast cancer. Raloxifene treatment was not associated with decreased breast
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density, but it did correlate with decreased breast magnetic resonance imaging volume, a
proposed surrogate biomarker for breast cancer risk.21
No relationship has been found between calcium/vitamin D intake and the risk of
postmenopausal breast cancer,22 but several studies suggest that high vitamin D intake, with
or without calcium, may protect against premenopausal breast cancer. Low calcium or vitamin
D intake has been associated with larger and higher grade breast tumors.23-25 Premenopausal
women who consumed at least 400 IU vitamin D and 1,000 mg calcium daily were noted to
have an 8.5% (95% confidence interval [CI], 1.8-15.1) lower mean breast density than those
who consumed less.26
Clinicopathologic Features, Biology, and Prognosis
The comparison of clinicopathologic and prognostic features of breast cancer arising in
younger women with those in their older counterparts has been the subject of published studies
for decades.27-29 Traditionally, breast cancer arising in a younger host is characterized by a
more aggressive phenotype. Among 185 premenopausal women carrying a diagnosis of
invasive breast cancer, referred for surgery at the European Institute of Oncology from April
1997 to August 2000, those aged less than 35 years had a higher percentage of ER-negative
(P <.001), progesterone receptor (PR)-negative (P <.001), vascular or lymphatic invasion
(48.6% υ 37.3%, P = .006) and pathologic grade 3 tumors (P <.0001) compared with women
aged 35-50 years.30 Differences in tumor size, lymph node involvement, and Her2/neu status
between younger and older women diagnosed with breast cancer have been less clear.30-33
Despite discrepancies in adverse prognostic features, younger age has been shown in several
studies to be an independent predictor of adverse outcome.31,32,34,35 A retrospective evaluation
of more than 1,200 women diagnosed with early-stage breast cancer evaluated the relationship
between age, typical prognostic factors, treatment, and patient outcome. Interestingly, age
younger than 35 proved to be a powerful independent prognostic factor in multivariate analyses,
including all potential patient, treatment, and pathology variables, and this was true for time
to recurrence (RR = 1.70, P <.001), time to distant failure (RR = 1.60, P <.009), and overall
mortality (RR = 1.50, P <.04).35 This thought-provoking analysis illustrates that young age,
after adjustment for all known prognostic factors, proves to be a powerful predictor of
recurrence risk and survival.
A second retrospective study evaluating more than 200,000 women in the SEER database, who
were diagnosed with breast cancer between the years of 1988-2003, revealed that those under
the age of 40 were 39% more likely to die when compared to those age 40 or older (hazard
ratio [HR] = 1.39; 95% CI, 1.34-1.45). Moreover, the highest mortality disparity between
younger (<40 years) and older women (≥40 years) was present in early stage, rather than later
stage disease. Specifically, women aged less than 40 were 44% and 9% more likely to die of
stage I (HR = 1.44; 95% CI, 1.27-1.64) and stage II breast cancer (HR = 1.09; 95% CI,
1.03-1.15), respectively.36,37 Although disparities in outcome between younger and older
women diagnosed with breast cancer have been attributed traditionally to adverse prognostic
features and later stage at diagnosis, this report implicates a unique biology unifying breast
cancer arising in the younger host. In addition, the “triple-negative” phenotype (ER−, PR−,
HER2−) of breast cancer, which is regarded as the most lethal type of the disease, is most
prevalent in young women, particularly in African Americans. In one study, triple-negative
breast cancer was found in 56% of black and 42% of white women aged 20-34 years.38
A comprehensive, large-scale genomic analysis was conducted to examine further the biology
of breast cancer arising in young women, with the goal of providing insight into this historically
aggressive disease process. Clinically annotated genomic expression data from more than 700
early-stage breast cancers were identified and placed within two age-defined cohorts (≤45 years
Anders et al. Page 3













and ≥65 years of age). Clinicopathologic results were consistent with previous reports
indicating that the younger women's breast tumors were larger (P = .012), of higher grade (P
= .0001), with more lymph node positivity (P = .008), lower ER positivity (P = .027), higher
rates of Her2/neu over-expression (P = .075), and a trend toward inferior disease-free survival
(HR = 1.32, P = .094).31 Moreover, genomic expression profiling demonstrated significantly
lower total mRNA levels of ERα, ERβ, and PR; with higher mRNA levels of both Her2/neu
and epithelial growth factor receptor (EGFR/Her1).31 Most importantly, application of the
statistical tool Gene Set Enrichment Analysis (GSEA) revealed 367 significant gene sets
enriched among young women's tumors, specifically distinguishing them from tumors arising
in older women.31 Representative gene sets included those involved with immune function,
hypoxia, BRCA1, stem cells, apoptosis, histone deacetylase, and multiple, targetable oncogenic
signaling pathways, including Myc, E2F, Ras, and mammalian target of rapamycin (mTOR).
31 This work provides one of the first substantiations that breast cancer arising in a younger
host is a unique entity characterized not only by adverse prognostic features, but also by a
diverse underlying biology against which novel therapeutics should be targeted.
Treatment and Management
Although the principles of managing invasive breast cancer in adolescent girls and young
women are the same as in older women, there are a number of management and therapeutic
issues requiring special consideration. Adolescents and young women are at particular risk of
emotional and psychosocial problems, and require appropriate support from age- and disease-
specific psychosocial and medical multidisciplinary teams.39
For many reasons, including development, function, body image, and quality of life, breast-
conserving surgery, whenever possible, is obviously desirable for most young women.
However, the two principle considerations when deciding between breast-conserving surgery
and mastectomy are the risk of local recurrence, as well as the overall cosmetic result. One of
the most important risk factors for local recurrence after breast-conserving surgery is age <35
years at presentation,40 as these patients were found to have a nine times higher risk of local
recurrence after conservative surgery than patients over 60 years of age.41 However, no studies
have demonstrated conservative surgery in young women to have a negative impact on survival.
All young women should be considered at high risk due to age alone, so adjuvant therapies
should be considered during management discussions.42 However, the use of adjuvant
therapies in young women raises issues of long term side effects, including the induction of an
early menopause, fertility impairment, and adverse effects on bone mineral density with
chemotherapy and endocrine therapies, and of the development of a second malignancy with
radiotherapy.
In addition to the appropriate use of radiotherapy, the current choices of adjuvant therapies for
premenopausal patients include cytotoxic chemotherapy, ovarian ablation (by surgery,
irradiation, or chemical ovarian suppression), anti-estrogen therapy, or any combination of
these modalities. However, the optimal combination of chemotherapy for young women has
become more controversial with the advent of recent studies examining the role of taxanes and
dose-intensive adjuvant therapies.43 Certainly it is clear that women under 30 years of age with
early-stage disease, who do not receive adjuvant chemotherapy, have particularly poor relapse-
free survival rates.44,45 At the current time, anthracycline-containing combinations remain the
standard of care. Such regimens have been shown to be more effective than a standard
cyclophosphamide, methotrexate, 5-fluorouracil (CMF) combination at 5 years of follow-up.
For example, cyclophosphamide, epirubicin, and 5-fluorouracil (CEF) compared with CMF
showed 5 year relapse-free and overall survival rates of 63% versus 53% (P = .009) and 77%
versus 70% (P = .03), respectively.46
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It is known that adjuvant chemotherapy for early breast cancer in patients under 50 years of
age reduces the relative risk of recurrence by 35% and of death by 27%, and adjuvant
chemotherapy alone has been shown to be appropriate for patients with ER-negative tumors.
47 However, 5 years of adjuvant tamoxifen has been shown to reduce the relative risk of
recurrence by 54% in women with ER-positive disease48 and, in the absence of
contraindications, all patients with ER-positive tumors diagnosed prior to age 40 require either
chemotherapy and endocrine therapy or endocrine therapy alone.
Other clinical trials have shown that patients with node-positive early breast cancer given four
cycles of doxorubicin and cyclophosphamide (AC) followed by four cycles of paclitaxel
demonstrated a 17% reduction in the risk of recurrence and an 18% reduction in the risk of
death compared with four cycles of AC alone,49,50 while the addition of docetaxel resulted in
a significant improvement in disease-free and overall survival for patients with one to three
positive lymph nodes.51 There is also a clear survival advantage for a dose-intense regimen of
AC followed by paclitaxel given every 2 weeks with growth factor support as, with a median
follow-up of 36 months, there is a 26% reduction in the risk of relapse (P = .010) and a 31%
reduction in the risk of death (P = .013) associated with the dose-intensive arms.52
Prior to the advent of targeted therapy for Her2-positive tumors with trastuzamab (Herceptin,
Genentech, San Francisco, CA), the ER−/PR-/HER2+ phenotype was associated with the
highest risk of breast cancer death. In the trastuzamab era, “triple-negative” tumors now have
the worst prognosis and, as mentioned earlier, young women have the highest proportion of
these tumors. The development of novel therapies for triple-negative tumors is a much needed
and fertile area for research.
Further compounding appropriate therapeutic management decisions is the evidence that
premenopausal women who achieve chemotherapy-induced amenorrhea demonstrate a better
prognosis than those retaining their menstrual cycle. It follows that amenorrhea may be
important in the action of chemotherapeutic agents. Both relapse-free and overall survival are
improved significantly by the induction of amenorrhea, although the optimal duration of
amenorrhea remains unknown.53-56 However, the likelihood of becoming amenorrheic
following adjuvant chemotherapy is inversely dependent on age. Therefore younger women
are less likely to gain maximum benefit from the endocrine effect of adjuvant chemotherapy.
57 Unfortunately, in trials evaluating ovarian suppression and amenorrhea to date,
chemotherapies used now would be viewed as suboptimal and the proportion of very young
women (<35 years) in the trials was small.55,58-60 It is difficult, therefore, to draw clear
conclusions regarding the potential benefit of chemotherapy-induced amenorrhea or ovarian
suppression. Conversely, suppression of ovarian function certainly has the potential to create
significant health and quality-of-life problems for very young women, including menopausal
symptoms, psychological distress, and the need to adjust personal and family plans. Further
trials are required to better evaluate the potential benefit of the addition of optimal endocrine
therapy to adjuvant chemotherapy in very young women.
Outcomes
Across all histologic subtypes and stages, breast cancer survival rates are comparatively lower
for women <40 years of age than for older women.13 The lowest overall rate of cancer survival
for females diagnosed during 2000-2005 was in those aged 25-29 years (72% 5-year relative
survival), followed by 20- to 24-year-olds and 30- to 34-year-olds (75% and 76%, respectively)
and 35- to 39-year-olds (80%) (Figure 5). In contrast, relative survival for women between age
45 and 80 years was 84%-86% (Figure 5). Fifteen to 19 year olds diagnosed with breast cancer
have an 80% survival rate at 5 years (Figure 5), but there is some suggestion that this group
may have increased mortality at older ages.13
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Not only has the survival of women with breast cancer been lower in those less than 40 years
at diagnosis, the improvement in survival since 1975 has been less in the younger women.
Hence, the discrepancy in survival between younger and older women became progressively
worse over the last quarter century (Figure 6). The relative improvement in older women and
lack of progress in younger women may be due to the age-dependent biological differences,
in that most of the therapeutic efforts have been conducted in middle-age and older women
with gratifying success, and not in young women whose cancers require a different treatment
approach.
Bleyer et al summarized the significantly worse survival in younger women for all stages of
breast cancer in comparison to older women.61 For 20- to 35-year-old women, compared with
women 45-75 years of age, 5-year relative survival for stage I-II breast cancer was 84% versus
92%, respectively; survival for stage III disease was 47% versus 55%; and for stage IV disease
was 15% versus 20% (Figure 7). The 5-year relative survival for women under 35 years of age
was also inferior for each histologic subtype of breast cancer, including infiltrating ductal,
medullary, lobular, and inflammatory breast cancer, as well as Paget's disease of the breast.
Young African American women have a disproportionately high breast cancer mortality rate
in comparison to other racial groups. One study found that black women <40 had larger tumor
size, higher rates of local and distant metastasis, a higher proportion of ER-negativity, and a
higher rate of medullary tumors. Relative risk for death was 1.94 for localized disease, 1.58
for regional disease, and 2.32 for metastatic disease compared to white women.62 Another
study showed comparable survival rates in premenopausal black women with early-stage
disease, compared to the general population. However, young black women with stages III and
IV disease had a worse prognosis despite standard therapy.63 Because 10% of black women
(υ 5% of white women) with breast cancer are diagnosed prior to age 40, and because young
black women have worse outcomes, some authors have suggested considering 30- to 39-year-
old black women as a high-risk group, and offering them routine mammographic screening.22
After black women, the highest mortality in young women is seen in Latinas, followed closely
by white, non-Hispanic; native American; and Asian women.13,64 Interestingly, and in contrast
to women in the United States, women <40 years of age in Asia did not have worse outcomes
compared to older women, despite more advanced disease at diagnosis and higher grade
tumors, suggesting an environmental role for outcome discrepancies.65
Decreases in mortality between 1975 and 2000 were three times greater for whites than for
blacks under age 40 years.13 Despite this overall improvement, survival for local breast cancer
in women aged 15-29 years, as well as for regional breast cancer in women aged 15-44 years,
actually decreased slightly between 1975 and 2000.13
Young women treated for breast cancer have disproportionately high rates of second
malignancies. Compared to older patients, women under age 50 treated for breast cancer have
a significantly increased incidence of tumors of bone, ovary, thyroid, kidney, lung, as well as
non-melanoma skin cancer, leukemia, and lymphoma.66 In addition, women under age 36
treated for early-stage breast cancer have been observed to have a 13% 10-year cumulative
incidence of contralateral breast cancer.66 Both post-lumpectomy radiation therapy (compared
with post-mastectomy radiation therapy and/or chemotherapy) and positive family history
appear to increase the risk of contralateral breast cancer in young women. In one study, breast
cancer patients under the age of 35 treated with radiotherapy had an increased risk for
contralateral breast cancer compared to patients treated at older ages (HR = 1.78; 95% CI,
0.85-3.72). The use of post-lumpectomy, compared to post-mastectomy, radiation conferred
an additional 50% increased risk of contralateral breast cancer in women under 45 years of
age. Interestingly, patients with a strong family history of breast cancer had even higher than
Anders et al. Page 6













expected rates of contralateral breast cancer following post-lumpectomy radiation. For all ages,
adjuvant chemotherapy decreased the rate of contralateral breast cancer for 5 years after
therapy, but not thereafter.67
Fertility and Pregnancy
Young women undergoing chemotherapy for breast cancer may struggle with fertility and
pregnancy issues. To that end, the American Society of Clinical Oncology has published
guidelines to address infertility.68 Unfortunately, there is no way to measure fertility other than
to follow patients for subsequent pregnancies and the use of amenorrhea as a surrogate marker
for infertility, which is imperfect. Also, many women may continue or resume menses months
after the administration of chemotherapy. Data suggest that young women who undergo
chemotherapy also may experience premature ovarian failure (POF).69
Risks of Infertility
Many of the chemotherapeutic agents used for breast cancer are associated with POF. Both the
agent and age of the patient impact on this risk. Goodwin et al57 evaluated 131 women who
received chemotherapy, either CMF or CEF, for breast cancer. The risk of menopause after 1
year approximated 50% by age 40 years. Recently, Reh et al70 evaluated the impact of
doxorubicin and cyclophosphamide (AC) and taxanes on rates of amenorrhea. The use of
taxanes did not impact the rate of amenorrhea or levels of estradiol or follicle-stimulating
hormone (FSH).
Fertility Preservation
Gonadotropin-releasing hormone analogues have been examined to preserve fertility.
However, these studies have been plagued with multiple design limitations and have used
resumption of menses as equivalent to fertility. Ismail-Khan et al71 presented a randomized
trial treating 49 women with chemotherapy ± triptorelin and found no benefit to preserving
menstrual status. A larger, prospective, randomized study from the Southwest Oncology Group
is currently accruing participants to address this question further, but only in patients with ER-
negative tumors. Other interventions, such as embryo cryopreservation, have shown the best
efficacy. Techniques such as oocyte cryopreservation and ovarian tissue cryopreservation and
transplantation, often orthotopically, are under investigation.68 Additionally, the use of
letrozole has been described in ovarian stimulation to avoid large estradiol surges, which may
be of concern for breast cancer patients.72
Pregnancy and Breast Cancer
Current estimates of breast cancer during pregnancy are 1.3 cases per 10,000 births73 and,
when cancer is diagnosed in women 30 years old or younger, an estimated 10%-20% of cancers
are detected either during pregnancy or within the first year postpartum.74,75
Breast Cancer Diagnosed During or After Pregnancy
Being pregnant at the time of diagnosis of breast cancer has been associated with a worse
outcome. In one study of 797 such cases, compared with 4,177 non-pregnancy-associated
breast cancer controls, women diagnosed while pregnant had larger, more advanced tumors, a
greater incidence of receptor-negative tumors, and a higher death rate (39.2% υ 33.4%, P = .
002).15 A smaller study found no association between pregnancy and increased mortality.76
In contrast, pregnancy and childbirth following a diagnosis of breast cancer do not increase
mortality, and actually may improve survival. One study found that 438 women age <45 years
at diagnosis, who delivered a child 10 or more months following a diagnosis of breast cancer,
had a decreased relative risk of death (RR = 0.54; 95% CI, 0.41-0.71), compared to women
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who did not bear children following diagnosis. Women who were pregnant at the time they
were diagnosed had a mortality rate similar to the latter group. This suggests that childbirth
following breast cancer diagnosis does not increase mortality.76
Physiologic changes in the breast may make self-palpation difficult. However, masses that do
not resolve within 1-2 weeks should be investigated.77 Imaging should include mammography
with proper shielding, as well as breast ultrasonography.78,79 A core biopsy of the mass should
be obtained. Staging to rule out metastatic disease can include magnetic resonance imaging
(MRI) of the thoracic and lumbar spines, a chest x-ray with fetal shielding and an ultrasound
of the liver. Computed tomography scans are not recommended during pregnancy due to fetal
radiation exposure. Once diagnosed, the woman should be seen in a multidisciplinary setting
with surgical oncology, radiation oncology, and maternal-fetal medicine.80
Breast surgery can be done safely in all trimesters of pregnancy, although many surgeons will
wait until the end of the first trimester when the rate of spontaneous abortion is lower.81
Radiation therapy is not done routinely for breast cancer until after delivery in order to avoid
radiation to the fetus. Chemotherapy has been administered safely during pregnancy in the
second and third trimesters.80 The largest prospective cohort of women treated prospectively
on a standardized protocol is from the University of Texas M.D. Anderson Cancer Center, with
5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. At the last
published update, 57 women had been treated, with 40 women alive and disease-free, three
women with recurrent breast cancer, 12 dying from breast cancer, one woman dying from
another cause, and one lost to follow-up. All women delivered live births with a median
gestational age of 37 weeks.81 Long-term follow-up on the children is needed and currently
underway. Other chemotherapies, such as taxanes, have been reported.82 The use of
trastuzumab should be avoided during pregnancy due to the concern of oligohydramnios and,
if warranted, started after delivery.83
Pregnancy Diagnosed During or After Breast Cancer
Studies of pregnancy after a diagnosis and treatment of breast cancer are retrospective and
most are case-controlled investigations. Although one study84 showed an increased risk for
relapse, most other studies show either no difference in recurrence or a decrease in risk of
recurrence.76 Breast cancer survivors and their medical caregivers are advised to fully discuss
the risk of recurrence when discussing post-cancer reproductive choices.
Bone Health
As a majority of young women diagnosed with early-stage breast cancer will survive many
years following diagnosis and treatment, bone loss associated with both adjuvant endocrine
and cytotoxic chemotherapeutics must be taken into consideration to prevent long-term
complications including osteopenia, osteoporosis, and potentially disabling fractures.
Traditionally, the postmenopausal breast cancer population had been the focus of bone health
research, given the success of aromatase inhibitors, agents well-known to cause bone loss
across both class and schedule.85 More recently, the adverse effects of premature menopause,
a common consequence of systemic therapies as described above, on future bone health are
receiving appropriate attention as accelerated bone loss has the potential to affect survivorship
significantly.
A recent analysis of more than 400 premenopausal women with early-stage breast cancer who
developed ovarian failure (defined as >3 months of amenorrhea and follicle-stimulating
hormone >30 U/L) following adjuvant chemotherapy, and then were treated with or without
zoledronic acid 4mg intravenously every 3 months (Zometa, Novartis Oncology, East Hanover,
NJ), reports a mean 6.4% decline in lumbar spine (LS) bone mineral density (BMD) among
Anders et al. Page 8













those who did not receive bisphosphonate therapy. Accelerated bone loss was prevented (2.8%
increase in LS BMD) among those who received zoledronic acid concurrent with adjuvant
chemotherapy, with a minimal side effect profile.86 A second randomized, double-blind, multi-
center phase III study evaluated the addition of zoledronic acid (4 mg intravenously every 3
months) versus placebo for 1 year among 101 women receiving chemotherapy for early-stage
breast cancer. Consistent with the previous report, placebo was associated with a significant
decline in LS BMD at both 6 (2.4%) and 12 (4.1%) months. In contrast, BMD remained stable
among patients receiving zoledronic acid (P <.0001).87 Therapy was well-tolerated and there
were no reports of either renal insufficiency or osteonecrosis of the jaw.
Finally, zoledronic acid has demonstrated anti-tumor and anti-metastatic activity in preclinical
and early clinical studies, providing a rationale for the recently reported Austrian Breast Cancer
Study Group (ABCSG) 12 trial. Over 1,800 premenopausal women with endocrine-responsive
early-stage breast cancer were randomized to ovarian suppression with the gonadotrophin-
releasing hormone (GnRH) agonist goserelin and tamoxifen or anastrozole (Arimidex,
AstraZeneca, Wilmington, Delaware) with or without zoledronic acid for 3 years. At a median
follow-up of 60 months, there was no significant difference in disease-free survival between
patients who received tamoxifen versus anastrozole alone (HR = 1.10; P = .59). However, the
addition of zoledronic acid to endocrine therapy significantly reduced the risk of events during
disease-free survival by 36% compared with endocrine therapy alone (HR = 0.64; P = .01),
and there was a nonsignificant trend in overall survival favoring therapy with zoledronic acid
(HR = 0.60; P = .10). Treatment was well-tolerated in all four study arms.88 The 5-year follow-
up of the ABCSG-12 BMD substudy also indicated stable BMD among those receiving
concomitant zoledronic acid, with bone loss observed among those receiving endocrine therapy
and ovarian suppression alone.89 Although formal guidelines do not yet exist, awareness of
the issue of BMD among young, premenopausal women facing systemic therapy for breast
cancer is paramount, and early incorporation of bisphosphonate therapy may improve not only
bone health but also breast cancer prognosis.
Inherited Breast Cancer and Risk Reduction
Family history is a known risk factor for breast cancer, with elevated risk due to both increasing
number and decreasing age of first-degree relatives affected. For example, in a large,
population-based study, risk of breast cancer was increased 2.9-fold among women whose
relative was diagnosed prior to age 30, but the increase was only 1.5-fold if the affected relative
was diagnosed after age 60 years.90 While twin studies indicate familial aggregation among
women diagnosed with breast cancer, identification of true germline mutations, including
BRCA1, BRCA2, p53 (Li Fraumeni), PTEN (Cowden's syndrome), and STK11 (Peutz-Jeghers),
are quite rare, on the order of 5%-6%.91-93 However, the management of young women at an
increased risk of developing breast cancer via a germline mutation requires careful
consideration, as screening, risk reduction, and implications for relatives are of upmost
importance.
BRCA1 and BRCA2, located on chromosomes 17 and 13, respectively, are thought to account
for the majority of inherited breast cancers.94 The estimated lifetime risks of developing breast
cancer among BRCA1 and BRCA2 carriers are 47%-66% and 40%-57%, respectively,
compared to a 12.5% risk among the general population.95 In addition, patients harboring
BRCA mutations are at higher lifetime risk for the development of ovarian cancer, bilateral
breast cancer, and male breast cancer; the last with BRCA2. Although there is no universal
approach, it is recommended that clinicians discuss intensive surveillance of the breasts and
ovaries, chemo-prevention, and prophylactic surgery (ie, bilateral mastectomy and bilateral
salpingo-oophorectomy) with their patients diagnosed with a BRCA mutation, on an
individualized basis. Specifically addressing breast surveillance, and according to the National
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mammography and clinical breast examination every 6-12 months is recommended among
women diagnosed with a genetic predisposition to breast cancer, beginning at 25 years of age.
Periodic self-examinations starting at age 18 years are encouraged. Bilateral breast MRI is
recommended as an adjunct to annual mammography and is also in accordance with the ACS
recommendations on MRI screening based on both observational and non-randomized
screening trials. In addition, the ACS recommends annual screening MRI as an adjunct to
mammography among women who have a first-degree relative diagnosed with a BRCA
mutation but remain untested themselves.96
Tamoxifen remains the only drug approved for risk reduction of breast cancer among high-
risk premenopausal women. Although the Study of Tamoxifen and Raloxifene (STAR) reports
raloxifene (Evista, Lilly, Indianapolis, IN) as being as effective as tamoxifen in reducing the
breast cancer risk among high-risk women, raloxifene is reserved for postmenopausal women
and should only be considered among premenopausal women in the setting of a clinical trial.
97 Recommendations for tamoxifen are based on the phase III National Surgical Adjuvant
Breast and Bowel Project (NSABP) chemo-prevention trial (BCPT-P1), which demonstrated
a 49% reduction in the incidence of invasive breast cancer (P <.0001) and a 50% reduction in
non-invasive breast cancer (P <.002) among 13,388 high-risk women randomized to tamoxifen
compared to placebo. Side effects associated with tamoxifen use were not inconsequential as
both endometrial cancer (RR = 2.5) and thrombotic events were more common among
tamoxifen-treated women.98 Subsequently, investigators sought to identify the effect of
tamoxifen on breast cancer incidence among women enrolled in the NSABP P-1 trial harboring
a BRCA1 or BRCA2 mutation. Results indicated a 62% risk reduction (RR = 0.38; 95% CI,
0.06-1.56) among BRCA2 carriers; however, there was no effect among BRCA1 carriers. This
difference is felt to be attributed to the higher incidence of ER-negative breast cancers
diagnosed among BRCA1 carriers and is consistent with the reduction in incidence of ER-
positive but not ER-negative tumors among all women enrolled in the NSABP P-1 trial.98,99
Identification of the optimal target population thought to benefit most from chemoprevention
remains to be determined, as does the effect of chemoprevention on overall survival.
Psychosocial Issues
Although a diagnosis of breast cancer can be distressing to patients across all age groups,
diagnosis at a younger age presents a variety of unique psychosocial and emotional challenges,
including, but not limited to, interactions with spouse/children, body image, sexuality, and loss
of fertility/premature menopause.69,100 A retrospective study evaluating more than 500 breast
cancer survivors aged 25-50 years illustrated that emotional and social functioning, vitality,
and depression 6 years (range, 2-10 years) following diagnosis were inversely proportional to
age at diagnosis.101 A clinical trial randomizing patients to mastectomy or breast-conserving
therapy evaluated 142 women prospectively for psychological response to their respective local
therapies. Six months following diagnosis, patients who underwent mastectomy reported
significantly less control over events in their lives (P = .003) and more difficulty with sexual
relations (P = .021) than did their conservatively treated counterparts.102
A novel web-based survey evaluating the effects of breast cancer diagnosis and treatment
among more than 600 young breast cancer survivors (median age, 32.9 years) indicated that
57% were concerned about infertility with treatment and 29% reported that these concerns
affected treatment decisions. Approximately 75% discussed these concerns with their
physicians and 51% felt that their concerns were addressed adequately.69 Finally, to address
the concern that psychosocial issues might play a role in cancer recurrence, a population-based
study of more than 700 Australian women aged less than 60 years was conducted. While this
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study did not reveal an association between breast cancer recurrence and measured
psychosocial factors, it did indicate that greater anxious preoccupation was associated with
younger age (P = .03).102 Currently, a large-scale clinical trial cosponsored by the Eastern
Cooperative Oncology Group and the National Cancer Institute is being conducted to evaluate
quality of life, including physical, psychological, social, and spiritual functioning, and women
aged less than 45 or over 55 years and their partners
(http://clinicaltrials.gov/ct2/show/NCT00309933; Principal Investigator: Victoria Champion,
DNS). This trial should provide invaluable insight into the needs of both patient populations.
Conclusions
Although thought to be a relatively uncommon condition, potentially one third of all breast
cancers are diagnosed among premenopausal women. Breast cancers diagnosed at a younger
age harbor aggressive clinicopathologic features and, more recently, have been recognized as
a unique biologic entity. Special considerations, including infertility, pregnancy, bone health,
genetic syndromes, and psychosocial issues must be addressed when developing treatment
algorithms, including local therapies and adjuvant chemotherapeutic/endocrine strategies,
among young women diagnosed with breast cancer. Finally, younger age at breast cancer
diagnosis confers an inferior prognosis when compared to older women, illustrating the need
for biologically driven clinical trials devoted specifically to the former population, with the
overall goal of improving outcome.
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Breast cancer in females by single year of age at diagnosis, SEER17, 2000-2005. The yellow
zone designates the 20- to 39-year age range.
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Cumulative percent of breast cancer in females, SEER17, 2000-2005.
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Incidence of breast cancer in females by 6-year eras, 1975-2000, SEER9.
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Incidence of breast cancer in females per calendar year, 2000-2004, SEER17.
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Five-year relative survival of females diagnosed with breast cancer during 2000-2005,
SEER17. The numbers above the bars designate the number of patients with breast cancer in
the SEER17 registry for 2000-2005. Data obtained on January 20, 2009 from the SEER
Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Limited-
Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2007 Sub (1973-2005 varying),
linked to county attributes, total US, 1969-2005 counties, National Cancer Institute, DCCPS,
Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the
November 2007 submission.
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Five-year relative survival of females diagnosed with breast cancer during 1975-1999 by stage,
SEER9. The numbers in parentheses designate the number of patients with breast cancer in the
SEER9 registry for 2000-2005. Data obtained on from SEER Program
(www.seer.cancer.gov) SEER*Stat Database: Incidence–SEER9.
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Ten-year relative survival of females diagnosed with breast cancer during 1975-1980,
1981-1986 and 1987-1993, SEER9.
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Table 1
Risk of Breast Cancer as Function of Age Estimated From Women Diagnosed in the US SEER17 Registries,
2004
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